Switching Heart Medicines: Mavacamten to Aficamten
Treatments studied
Part of Heart & circulation clinical trials.
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have obstructive hypertrophic cardiomyopathy (HCM)—a thickened heart muscle that blocks blood flow—confirmed by heart ultrasound
- You are currently taking mavacamten and it's working well for you
- Your heart's pumping strength (ejection fraction) is at least 55% on your current dose
- You are willing to switch medications and attend follow-up visits for the study
- You do not have atrial fibrillation (irregular heart rhythm) that is not controlled with blood thinners
- You do not have severe narrowing of coronary arteries (the blood vessels supplying your heart)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called aficamten in people with non-obstructive hypertrophic cardiomyopathy (a thickened heart muscle that affects how well the heart works). The goal is to see if it improves symptoms like fatigue and shortness of breath and helps you feel better in daily life.
This study tests whether mavacamten, a medication that may help the heart use energy better, can improve symptoms in people with obstructive hypertrophic cardiomyopathy. It aims to see if this drug helps with chest pain and shortness of breath, and improve overall heart function.
This trial tests if mavacamten can help people with hypertrophic cardiomyopathy (HCM) who have obstruction in the middle or tip of the heart (not the usual outflow tract). You may join if you have symptoms like chest pain or shortness of breath and a pressure gradient above 30 mmHg in these areas.
This study looks at how a drug called mavacamten, which relaxes the heart muscle, works in people with obstructive hypertrophic cardiomyopathy. It uses genetic testing to try to predict who will respond best to the drug.
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
Hear when a new Hypertrophic Cardiomyopathy (HCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.